{"result": "(\"entity\"<|>LIRAGLUTIDA<|>ORGANIZATION<|>Liraglutida is a medication used for weight loss, showing significant efficacy in clinical trials for obesity treatment.)\n##\n(\"entity\"<|>BUPROPION-ZONISAMIDA<|>ORGANIZATION<|>Bupropion-zonisamida is a drug combination being tested for weight loss.)\n##\n(\"entity\"<|>FENTERMINA-LORCASERINA<|>ORGANIZATION<|>Fentermina-lorcaserina is another drug combination under investigation for obesity treatment.)\n##\n(\"entity\"<|>BLOSSOM TRIAL<|>EVENT<|>The BLOSSOM trial is a clinical study evaluating the effectiveness of lorcaserin for weight loss in obese and overweight adults.)\n##\n(\"entity\"<|>BLOOM-DM STUDY<|>EVENT<|>The BLOOM-DM study is a clinical trial assessing lorcaserin's impact on weight loss in individuals with type 2 diabetes mellitus.)\n##\n(\"entity\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>ORGANIZATION<|>The American College of Cardiology is a professional organization that provides guidelines for the management of obesity and overweight in adults.)\n##\n(\"entity\"<|>AMERICAN HEART ASSOCIATION<|>ORGANIZATION<|>The American Heart Association is an organization that collaborates on guidelines for obesity management.)\n##\n(\"entity\"<|>OBESITY SOCIETY<|>ORGANIZATION<|>The Obesity Society is a professional organization focused on the study and treatment of obesity.)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>BUPROPION-ZONISAMIDA<|>Both Liraglutida and Bupropion-zonisamida are medications being tested for weight loss, indicating a relationship in the context of obesity treatment.<|>5)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>FENTERMINA-LORCASERINA<|>Both Liraglutida and Fentermina-lorcaserina are drug combinations being investigated for their effectiveness in treating obesity.<|>5)\n##\n(\"relationship\"<|>BLOSSOM TRIAL<|>LIRAGLUTIDA<|>The BLOSSOM trial specifically evaluates the effectiveness of Liraglutida for weight loss, establishing a direct relationship.<|>8)\n##\n(\"relationship\"<|>BLOOM-DM STUDY<|>LIRAGLUTIDA<|>The BLOOM-DM study assesses the impact of Liraglutida on weight loss in type 2 diabetes patients, indicating a strong relationship.<|>8)\n##\n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>BLOSSOM TRIAL<|>The American College of Cardiology provides guidelines that may influence the design and outcomes of trials like BLOSSOM, indicating a relationship in the context of obesity management.<|>4)\n##\n(\"relationship\"<|>AMERICAN HEART ASSOCIATION<|>BLOSSOM TRIAL<|>The American Heart Association collaborates on obesity management guidelines that may impact studies like the BLOSSOM trial, indicating a relationship.<|>4)\n##\n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>AMERICAN HEART ASSOCIATION<|>Both organizations work together to provide comprehensive guidelines for the management of obesity, indicating a collaborative relationship.<|>6)\n##\n(\"relationship\"<|>AMERICAN COLLEGE OF CARDIOLOGY<|>OBESITY SOCIETY<|>The American College of Cardiology collaborates with the Obesity Society to develop guidelines for obesity management, indicating a relationship.<|>5)\n##\n(\"relationship\"<|>AMERICAN HEART ASSOCIATION<|>OBESITY SOCIETY<|>The American Heart Association works with the Obesity Society to create guidelines for obesity treatment, indicating a collaborative relationship.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: liraglutida 3 mg, conseguían perder ≥ 5% del peso ini-                 efectos secundarios. Se están ensayando asociaciones\ncial al cabo de un año. El 77,3% de los participantes                  de fármacos conocidos como bupropión-zonisamida o\ntratados con el fármaco se encuentran en esta catego-                  de fentermina-lorcaserina. Pero, son los agonistas dua-\nría de respondedores tempranos; y la pérdida prome-                    les o triagonistas de hormonas gastrointestinales (GLP1\ndio de peso a las 56 semanas fue de –10,8% (frente a                   junto a análogos de glucagón, oxintomodulina o GIP),\n–3% de los no respondedores tempranos)31.                              los que están ocupando las primeras líneas de investi-\n---\n                                                                            Tema 8.    Tratamiento farmacológico de la obesidad              139\n\n\n\n%\n\n\n\n           10            15/92 mg\n             9         8,9\n             8                   7,5/45 mg\n             7                6,6                  F-II/SCALE\n             6                                  5,9                         COR-I/II/BMOD\n             5                                           SCALE-DM        4,7\n             4                                         4,0                          COR-DM          BLOOM-BLOSSOMBLOOM-DM     Metanálisis\n                                                                                3,3               3,3    3,1               2,9\n             3\n             2\n             1\n             0\n                      Fent/Topir               LIRA 3 mg              BN 360/32 mg               Lorcaserina            Orlistat\n\n\n\n   Figura 2.    Eficacia en la pérdida de peso a un año según diferentes fármacos comercializados: diferencia con\n   placebo (análisis por intención de tratar).\n\n\n\n   gación más sólidas35-38. Estos nuevos fármacos tendrán                       6.  Fidler MC, Sanchez M, Raether B, Weissman NJ,\n   que superar los efectos secundarios a nivel central y de                         Smith SR, Shanahan WR, Anderson CM; BLOSSOM\n   riesgo cardiovascular que han hecho fracasar en el pa-                           Clinical Trial Group. A one-year randomized trial of\n   sado a otros que les precedieron.                                                lorcaserin for weight loss in obese and overweight\n                                                                                    adults: the BLOSSOM trial. J Clin Endocrinol Metab\n   5.   Bibliografía                                                                2011; 96:3067-3077.\n                                                                                7.  Smith SR, Weissman NJ, Anderson CM, Sanchez M,\n   1.  Jensen MD, Ryan DH, Apovian CM, Ard JD, Co-                                  Chuang E, Stubbe S, Bays H, Shanahan WR. Multi-\n       muzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS                                center, placebo-controlled trial of lorcaserin for\n       guideline for the management of overweight and                               weight management. N Engl J Med 2010; 363:245-\n       obesity in adults: a report of the American College                          256.\n       of Cardiology/American Heart Association Task For-                       8.  O’Neil PM, Smith SR, Weissman NJ, Fidler MC,\n       ce on Practice Guidelines and The Obesity Society. J                         Sanchez M, Zhang J, Raether B, Anderson CM,\n       Am Coll Cardiol. 2014; 63(25 Pt B): 2985-3023.                               Shanahan WR. Randomized placebo controlled\n   2.  Middleton KM, Patidar SM, Perri MG. The impact of                            clinical trial of lorcaserin for weight loss in type 2\n       extended care on the long-term maintenance of                                diabetes mellitus: the BLOOM-DM study. Obesity\n       weight loss: a systematic review and meta-analysis.                          2012; 20: 1426-1436.\n       Obesity Rev. 2012; 13: 509-17.                                           9.  Khera R, Murad MH, Chandar AK, Dulai PS, Wang\n   3.  Krentz AJ, Fujioka K,Hompesch M. Evolution of                                Z, Prokop LJ, et al. Association of pharmacological\n       pharmacological obesity treatments: focus on ad-                             treatments for obesitywithweight loss and adverse\n       verse side-effect profiles. Diabetes Obes Metabol.                           events. A systematic review and meta-analysis.\n       2016; 18: 558-570.                                                           JAMA. 2016; 315: 2424-34.\n   4.  Cabrerizo-García L, Ramos-Leví A, Moreno-Lopera                        10.   Garvey WT, Mechanick JI, Brett EM, Garber AJ,\n       C, Rubio-Herrera MA. Update on pharmacology of                               Hurley DL, Jastreboff AM, et al. American Asso-\n       obesity: Benefits and risks. Nutr Hosp 2013; 28 Sup-                         ciation of Clinical Endocrinologists and Ameri-\n       pl 5:121-7.                                                                  can   College     of  Endocrinology        comprehensive\n   5\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}